Adaptive designs for multi-armed clinical trials have become increasingly popular recently because of their potential to shorten development times and to increase patient response. However, developing response-adaptive designs that offer patient-benefit while ensuring the resulting trial provides a statistically rigorous and unbiased comparison of the different treatments included is highly challenging. In this paper, the theory of is used to define near optimal adaptive designs in the context of a clinical trial with a normally distributed endpoint with known variance. We report the operating characteristics (type I error, power, bias) and patient-benefit of these approaches and alternative designs using simulation studies based on an ongoing trial. These results are then compared to those recently published in the context of Bernoulli endpoints. Many limitations and advantages are similar in both cases but there are also important differences, specially with respect to type I error control. This paper proposes a simulation-based testing procedure to correct for the observed type I error inflation that bandit-based and adaptive rules can induce.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856359 | PMC |
http://dx.doi.org/10.1080/02664763.2017.1342780 | DOI Listing |
Alzheimers Dement
December 2024
Washington University School of Medicine, St. Louis, MO, USA.
Background: The well-accepted statistical efficacy inference approach for Alzheimer's disease (AD) clinical trials compares the absolute difference in change from baseline at the last study visit using MMRM (henceforth referred to as MMRM-Last-Visit). Recent AD clinical trials have shown that treatment effects may be manifested prior to 18 months. The objective is to evaluate models estimating an overall treatment effect across all post-baseline visits that may characterize disease modifying effects in contemporary early AD clinical trials.
View Article and Find Full Text PDFBackground: In AD trials, the treatment effect is typically evaluated by estimating the absolute difference in change from baseline to the end-of-study visit (e.g., 18 months) between treatment arms using the MMRM model.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Cumulus Neuroscience, Dublin, Ireland.
Background: Current tools for Alzheimer's disease screening and staging used in clinical research (e.g. ACE-3, ADAS-Cog) require substantial face-to-face time with trained professionals, and may be affected by subjectivity, "white coat syndrome" and other biases.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Brighton and Sussex Medical School, Brighton, UK.
Background: Walking is a key facilitator of healthy ageing and may reduce risk of cognitive decline in older adults. To develop suitable, accessible interventions, we must objectively consider the socio-ecological factors which influence participation in walking activities. For example, walking may be influenced by the volume and type of activities one's partner participates in (i.
View Article and Find Full Text PDFJ Surg (Lisle)
November 2024
Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Purpose: Appropriate opioid management is crucial to reduce opioid overdose risk for ICU surgical patients, which can lead to severe complications. Accurately predicting postoperative opioid needs and understanding the associated factors can effectively guide appropriate opioid use, significantly enhancing patient safety and recovery outcomes. Although machine learning models can accurately predict postoperative opioid needs, lacking interpretability hinders their adoption in clinical practice.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!